Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

TRAIL and Ceruloplasmin Inverse Correlation as a Representative Crosstalk between Inflammation and Oxidative Stress.

Tisato V, Gallo S, Melloni E, Celeghini C, Passaro A, Zauli G, Secchiero P, Bergamini C, Trentini A, Bonaccorsi G, Valacchi G, Zuliani G, Cervellati C.

Mediators Inflamm. 2018 Jul 26;2018:9629537. doi: 10.1155/2018/9629537. eCollection 2018.

2.

Neuronal Dysfunction Associated with Cholesterol Deregulation.

Marcuzzi A, Loganes C, Valencic E, Piscianz E, Monasta L, Bilel S, Bortul R, Celeghini C, Zweyer M, Tommasini A.

Int J Mol Sci. 2018 May 19;19(5). pii: E1523. doi: 10.3390/ijms19051523.

3.

Pre-eclampsia affects procalcitonin production in placental tissue.

Agostinis C, Rami D, Zacchi P, Bossi F, Stampalija T, Mangogna A, Amadio L, Vidergar R, Vecchi Brumatti L, Ricci G, Celeghini C, Radillo O, Sargent I, Bulla R.

Am J Reprod Immunol. 2018 Apr;79(4):e12823. doi: 10.1111/aji.12823. Epub 2018 Feb 10.

PMID:
29427369
4.

Repositioning of Tak-475 In Mevalonate Kinase Disease: Translating Theory Into Practice.

Marcuzzi A, Loganes C, Celeghini C, Kleiner G.

Curr Med Chem. 2018;25(24):2783-2796. doi: 10.2174/0929867324666170911161417. Review.

PMID:
28901277
5.

PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines.

Ultimo S, Simioni C, Martelli AM, Zauli G, Evangelisti C, Celeghini C, McCubrey JA, Marisi G, Ulivi P, Capitani S, Neri LM.

Oncotarget. 2017 Apr 4;8(14):23213-23227. doi: 10.18632/oncotarget.15542.

6.

Complement component C1q as potential diagnostic but not predictive marker of preeclampsia.

Agostinis C, Stampalija T, Tannetta D, Loganes C, Vecchi Brumatti L, De Seta F, Celeghini C, Radillo O, Sargent I, Tedesco F, Bulla R.

Am J Reprod Immunol. 2016 Dec;76(6):475-481. doi: 10.1111/aji.12586. Epub 2016 Sep 26.

PMID:
27666323
7.

Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.

Voltan R, Rimondi E, Melloni E, Rigolin GM, Casciano F, Arcidiacono MV, Celeghini C, Cuneo A, Zauli G, Secchiero P.

Oncotarget. 2016 Oct 25;7(43):70623-70638. doi: 10.18632/oncotarget.12139.

8.

Geranylgeraniol and Neurological Impairment: Involvement of Apoptosis and Mitochondrial Morphology.

Marcuzzi A, Piscianz E, Zweyer M, Bortul R, Loganes C, Girardelli M, Baj G, Monasta L, Celeghini C.

Int J Mol Sci. 2016 Mar 11;17(3):365. doi: 10.3390/ijms17030365.

9.

Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity.

Trapella C, Voltan R, Melloni E, Tisato V, Celeghini C, Bianco S, Fantinati A, Salvadori S, Guerrini R, Secchiero P, Zauli G.

J Med Chem. 2016 Jan 14;59(1):147-56. doi: 10.1021/acs.jmedchem.5b01165. Epub 2015 Dec 23.

PMID:
26653539
10.

TNF-related apoptosis inducing ligand in ocular cancers and ocular diabetic complications.

Perri P, Zauli G, Gonelli A, Milani D, Celeghini C, Lamberti G, Secchiero P.

Biomed Res Int. 2015;2015:424019. doi: 10.1155/2015/424019. Epub 2015 Mar 5. Review.

11.

Levels of circulating TNF-related apoptosis-inducing ligand in celiac disease.

Celeghini C, Not T, Norcio A, Monasta L, Secchiero P.

Exp Ther Med. 2014 Dec;8(6):1906-1908. Epub 2014 Oct 15.

12.

Potential role of circulating microRNAs as early markers of preeclampsia.

Ura B, Feriotto G, Monasta L, Bilel S, Zweyer M, Celeghini C.

Taiwan J Obstet Gynecol. 2014 Jun;53(2):232-4. doi: 10.1016/j.tjog.2014.03.001.

13.

Association of serum tumor necrosis factor-related apoptosis inducing ligand with body fat distribution as assessed by dual X-rays absorptiometry.

Cervellati C, Secchiero P, Bonaccorsi G, Celeghini C, Zauli G.

Mediators Inflamm. 2014;2014:306848. doi: 10.1155/2014/306848. Epub 2014 May 21.

14.

Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3.

Agnoletto C, Melloni E, Casciano F, Rigolin GM, Rimondi E, Celeghini C, Brunelli L, Cuneo A, Secchiero P, Zauli G.

Oncotarget. 2014 Jun 30;5(12):4347-60.

15.

Soluble TRAIL is present at high concentrations in seminal plasma and promotes spermatozoa survival.

Zauli G, Celeghini C, Monasta L, Martinelli M, Luppi S, Gonelli A, Grill V, Ricci G, Secchiero P.

Reproduction. 2014 Aug;148(2):191-8. doi: 10.1530/REP-14-0144. Epub 2014 May 13.

PMID:
24825910
16.

Upregulation of SOCS-1 by Nutlin-3 in acute myeloid leukemia cells but not in primary normal cells.

Tisato V, Norcio A, Celeghini C, Milani D, Gonelli A, Secchiero P.

Clinics (Sao Paulo). 2014 Jan;69(1):68-74. doi: 10.6061/clinics/2014(01)10.

17.

NF-κB pathways in hematological malignancies.

Gasparini C, Celeghini C, Monasta L, Zauli G.

Cell Mol Life Sci. 2014 Jun;71(11):2083-102. doi: 10.1007/s00018-013-1545-4. Epub 2014 Jan 14. Review.

PMID:
24419302
18.

MDM2 non-genotoxic inhibitors as innovative therapeutic approaches for the treatment of pediatric malignancies.

Tisato V, Norcio A, Voltan R, Celeghini C, Zella D, Secchiero P.

Curr Med Chem. 2013;20(17):2226-36. Review.

PMID:
23458617
19.

Release of a specific set of proinflammatory adipokines by differentiating 3T3-L1 cells.

Melloni E, Zauli G, Celeghini C, Volpi I, Secchiero P.

Nutrition. 2013 Jan;29(1):332-7. doi: 10.1016/j.nut.2012.07.013.

PMID:
23237655
20.

The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.

Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M, di Iasio MG, Lanza F, Secchiero P.

Haematologica. 2012 Nov;97(11):1722-30. doi: 10.3324/haematol.2012.062083. Epub 2012 Jun 11.

21.

MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib.

Secchiero P, Melloni E, Voltan R, Norcio A, Celeghini C, Zauli G.

Br J Haematol. 2012 May;157(4):510-4. doi: 10.1111/j.1365-2141.2012.09042.x. Epub 2012 Feb 8. No abstract available.

PMID:
22313359
22.

Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells.

Corallini F, Celeghini C, Rimondi E, di Iasio MG, Gonelli A, Secchiero P, Zauli G.

J Cell Physiol. 2011 Sep;226(9):2279-86. doi: 10.1002/jcp.22564.

PMID:
21660951
23.

Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells.

Rimondi E, di Iasio MG, Gonelli A, Celeghini C, Secchiero P, Zauli G.

Invest New Drugs. 2012 Aug;30(4):1731-5. doi: 10.1007/s10637-011-9675-8. Epub 2011 May 4. No abstract available.

PMID:
21541705
24.

Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside.

Bosco R, Melloni E, Celeghini C, Rimondi E, Vaccarezza M, Zauli G.

Mini Rev Med Chem. 2011 Mar;11(3):185-99. Review.

PMID:
21534929
25.

Recent advances in the therapeutic perspectives of Nutlin-3.

Secchiero P, Bosco R, Celeghini C, Zauli G.

Curr Pharm Des. 2011;17(6):569-77. Review.

PMID:
21391907
26.

Total extract of Beta vulgaris var. cicla seeds versus its purified phenolic components: antioxidant activities and antiproliferative effects against colon cancer cells.

Gennari L, Felletti M, Blasa M, Angelino D, Celeghini C, Corallini A, Ninfali P.

Phytochem Anal. 2011 May-Jun;22(3):272-9. doi: 10.1002/pca.1276. Epub 2011 Feb 19.

PMID:
21337646
27.

Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells.

Bosco R, Rabusin M, Voltan R, Celeghini C, Corallini F, Capitani S, Secchiero P.

Invest New Drugs. 2012 Feb;30(1):417-22. doi: 10.1007/s10637-010-9564-6. Epub 2010 Oct 16.

PMID:
20953816
28.

Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes.

Zauli G, Toffoli B, di Iasio MG, Celeghini C, Fabris B, Secchiero P.

Diabetes. 2010 May;59(5):1261-5. doi: 10.2337/db09-1771. Epub 2010 Feb 25.

29.

Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines.

Celeghini C, Voltan R, Rimondi E, Gattei V, Zauli G.

Invest New Drugs. 2011 Apr;29(2):392-5. doi: 10.1007/s10637-009-9370-1. Epub 2010 Feb 4.

PMID:
20130960
30.

Perifosine plus nutlin-3 combination shows a synergistic anti-leukaemic activity.

Voltan R, Celeghini C, Melloni E, Secchiero P, Zauli G.

Br J Haematol. 2010 Mar;148(6):957-61. doi: 10.1111/j.1365-2141.2009.08018.x. Epub 2009 Dec 1. No abstract available.

PMID:
19958355
31.

Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo.

Candido R, Toffoli B, Corallini F, Bernardi S, Zella D, Voltan R, Grill V, Celeghini C, Fabris B.

J Vasc Res. 2010;47(3):252-61. doi: 10.1159/000257339. Epub 2009 Nov 11.

32.

Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL).

Zauli G, Rimondi E, Celeghini C, Milani D, Secchiero P.

J Cell Physiol. 2010 Feb;222(2):357-64. doi: 10.1002/jcp.21960.

PMID:
19877156
33.

Activation of PKC-epsilon counteracts maturation and apoptosis of HL-60 myeloid leukemic cells in response to TNF family members.

Gonelli A, Milani D, Rimondi E, Voltan R, Grill V, Celeghini C.

Eur J Histochem. 2009 Sep 23;53(3):177-82.

PMID:
19864212
34.

The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia.

Secchiero P, di Iasio MG, Melloni E, Voltan R, Celeghini C, Tiribelli M, Dal Bo M, Gattei V, Zauli G.

Leukemia. 2010 Feb;24(2):480-3. doi: 10.1038/leu.2009.215. Epub 2009 Oct 22. No abstract available.

PMID:
19847196
35.

Activation of PKC-ε counteracts maturation and apoptosis of HL-60 myeloid leukemic cells in response to TNF family members.

Gonelli A, Milani D, Rimondi E, Voltan R, Grill V, Celeghini C.

Eur J Histochem. 2009 Sep 30;53(3):e21. doi: 10.4081/ejh.2009.e21. eCollection 2009 Sep 30. Review.

36.

An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies.

Macor P, Secco E, Zorzet S, Tripodo C, Celeghini C, Tedesco F.

Curr Pharm Des. 2008;14(21):2023-39. Review.

PMID:
18691113
37.

The potential role of Nutlins in the treatment of B-chronic lymphocytic leukemia (B-CLL).

Corallini F, Celeghini C.

J Leukoc Biol. 2008 Sep;84(3):651. doi: 10.1189/jlb.0408222. Epub 2008 Jun 2. No abstract available.

PMID:
18519745
38.

Effect of recombinant TRAIL in a murine co-culture system of osteoclastogenesis.

Nicolin V, Narducci P, Celeghini C.

Eur J Histochem. 2008 Jan-Mar;52(1):75-8.

PMID:
18502726
39.

Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.

Barbarotto E, Corallini F, Rimondi E, Fadda R, Mischiati C, Grill V, Vaccarezza M, Celeghini C.

J Cell Biochem. 2008 May 15;104(2):595-605.

PMID:
18092340
40.

Recombinant TRAIL induces miorelaxating activity in rat aortas, which is abrogated by the induction of diabetes mellitus.

Celeghini C, Bortul R, Fadda R, Gonelli A.

Atherosclerosis. 2007 May;192(1):224-6. Epub 2007 Mar 26. No abstract available.

PMID:
17386927
41.

Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo.

Zauli G, Corallini F, Bossi F, Fischetti F, Durigutto P, Celeghini C, Tedesco F, Secchiero P.

Blood. 2007 Jul 15;110(2):536-43. Epub 2007 Mar 15.

42.

Insulin down-regulates TRAIL expression in vascular smooth muscle cells both in vivo and in vitro.

Corallini F, Celeghini C, Rizzardi C, Pandolfi A, Di Silvestre S, Vaccarezza M, Zauli G.

J Cell Physiol. 2007 Jul;212(1):89-95.

PMID:
17352408
43.

An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction.

Secchiero P, Corallini F, Pandolfi A, Consoli A, Candido R, Fabris B, Celeghini C, Capitani S, Zauli G.

Am J Pathol. 2006 Dec;169(6):2236-44.

44.

Potential pathogenetic implications of cyclooxygenase-2 overexpression in B chronic lymphoid leukemia cells.

Secchiero P, Barbarotto E, Gonelli A, Tiribelli M, Zerbinati C, Celeghini C, Agostinelli C, Pileri SA, Zauli G.

Am J Pathol. 2005 Dec;167(6):1599-607.

45.

Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells.

Secchiero P, Tiribelli M, Barbarotto E, Celeghini C, Michelutti A, Masolini P, Fanin R, Zauli G.

J Cell Physiol. 2005 Nov;205(2):246-52.

PMID:
15887227
46.

Functional expression of TRAIL and TRAIL-R2 during human megakaryocytic development.

Melloni E, Secchiero P, Celeghini C, Campioni D, Grill V, Guidotti L, Zauli G.

J Cell Physiol. 2005 Sep;204(3):975-82.

PMID:
15828026
47.

Modulation of the expression and activity of cyclooxygenases in normal and accelerated erythropoiesis.

Rocca B, Secchiero P, Celeghini C, Ranelletti FO, Ciabattoni G, Maggiano N, Habib A, Ricerca BM, Barbarotto E, Patrono C, Zauli G.

Exp Hematol. 2004 Oct;32(10):925-34.

PMID:
15504548
48.

TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF.

Zauli G, Rimondi E, Nicolin V, Melloni E, Celeghini C, Secchiero P.

Blood. 2004 Oct 1;104(7):2044-50. Epub 2004 Jun 22.

49.

Association of PI 3-K with tyrosine phosphorylated Vav is essential for its activity in neutrophil-like maturation of myeloid cells.

Bertagnolo V, Brugnoli F, Marchisio M, Celeghini C, Carini C, Capitani S.

Cell Signal. 2004 Apr;16(4):423-33.

PMID:
14709332
50.

Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells.

Milani D, Zauli G, Rimondi E, Celeghini C, Marmiroli S, Narducci P, Capitani S, Secchiero P.

J Neurochem. 2003 Jul;86(1):126-35.

Supplemental Content

Loading ...
Support Center